130 related articles for article (PubMed ID: 38732502)
1. Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency.
Cesarano D; Borrelli S; Campilongo G; D'Ambra A; Papadia F; Garofalo C; De Marco A; Marzano F; Ruotolo C; Gesualdo L; Cirillo P; Minutolo R
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732502
[TBL] [Abstract][Full Text] [Related]
2. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.
Pisani A; Riccio E; Sabbatini M; Andreucci M; Del Rio A; Visciano B
Nephrol Dial Transplant; 2015 Apr; 30(4):645-52. PubMed ID: 25395392
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
4. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
6. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron.
Gotloib L; Silverberg D; Fudin R; Shostak A
J Nephrol; 2006; 19(2):161-7. PubMed ID: 16736414
[TBL] [Abstract][Full Text] [Related]
7. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ
Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
Ambrosy AP; von Haehling S; Kalra PR; Court E; Bhandari S; McDonagh T; Cleland JGF
Am J Cardiol; 2021 Aug; 152():138-145. PubMed ID: 34162484
[TBL] [Abstract][Full Text] [Related]
9. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R; Berru F; Panwar B; Gutiérrez OM
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
[TBL] [Abstract][Full Text] [Related]
11. Real-world experience of intravenous iron sucrose supplementation and dynamics of soluble transferrin receptor and hepcidin in a Spanish cohort of absolute iron deficient patients.
Tarancon-Diez L; Iriarte-Gahete M; Sanchez-Mingo P; Perez-Cabeza G; Romero-Candau F; Pacheco YM; Leal M; Muñoz-Fernández MÁ
Biomed Pharmacother; 2023 Nov; 167():115510. PubMed ID: 37757490
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
Valério de Azevedo S; Maltez C; Lopes AI
Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
[TBL] [Abstract][Full Text] [Related]
14. Response of hemoglobin, serum ferritin, and serum transferrin receptor during iron supplementation in pregnancy: a prospective study.
Madhavan Nair K; Bhaskaram P; Balakrishna N; Ravinder P; Sesikeran B
Nutrition; 2004 Oct; 20(10):896-9. PubMed ID: 15474878
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation.
Barton JC; Barton EH; Bertoli LF; Gothard CH; Sherrer JS
Am J Med; 2000 Jul; 109(1):27-32. PubMed ID: 10936475
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
17. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
18. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
[TBL] [Abstract][Full Text] [Related]
20. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
